期刊
PEDIATRIC BLOOD & CANCER
卷 69, 期 9, 页码 -出版社
WILEY
DOI: 10.1002/pbc.29786
关键词
chronic myeloid leukemia; late effects of cancer treatment; tyrosine kinase inhibitor
Tyrosine kinase inhibitors (TKIs) have improved prognosis for pediatric leukemia, but this study suggests that TKI exposure may lead to late-onset complications. The results indicate that children receiving TKI treatment may face long-term health risks.
Background Tyrosine kinase inhibitors (TKIs) improve outcomes for pediatric malignancies characterized by specific gene rearrangements and mutations; however, little is known about the long-term impact of TKI exposure. Our objective was to assess the incidence and type of late-onset TKI-related toxicities in children with chronic myeloid leukemia (CML). Methods We reviewed medical records from patients diagnosed with CML between 2006 and 2019 at Twenty-two eligible TKI-exposed patients with CML were identified. The median follow-up was 6.0 years (range: 2.2-14.3). All pericardial (n = 3) or pleural (n = 3) effusion outcomes occurred in patients treated with TKIs during the data-capture period. Other outcomes included hypertension (n = 2), ectopy on electrocardiogram (n = 2), and gastrointestinal bleed (n = 1). All outcomes were graded as mild to moderate: some resulted in a temporary discontinuation of TKI, but none led to a change in TKI. No differences were noted in outcome incidence by type of TKI exposure. Conclusions TKIs have substantially improved prognosis for subsets of childhood leukemia, but there are limited long-term data to inform exposure-based risk for late-onset complications and screening. Our results suggest that TKI-exposed survivors may be at risk for long-term outcomes that extend well into survivorship.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据